T he conference sponsored by the International Society of Cancer Gene Therapy was held at the Cumberland Hotel in London, England, on July 12 -13, 2001. The meeting attracted participants from Europe, North America, and Asia. The leading scientific experts gave presentations focused on the basic science of gene delivery systems and the advances being made in clinical studies for cancer gene therapy. This meeting offered a forum for the fast -moving developments in the field of cancer gene therapy for medical researchers, the health care industry, and the regulatory agencies of national governments.
The organizing committee, consisting of Drs. F. Farzaneh, N. Habib, A. Miller, P. Walden, O. Eremin, and Ms. J. Nicholls, prepared an excellent program on Antitumor Immunity, Vector Development, Gene Therapy -Induced Tumor Apoptosis, Replication -Competent Viral Vectors, and updates on new Clinical Trials. Dr. Andrew Miller, president of the International Society of Cancer Gene Therapy, 2000 -2001, Dr. Nagy Habib, and Dr. Farzin Farzaneh opened the conference and gratefully thanked the sponsors. The five top posters were each awarded a financial prize as judged by the organizing committee at the end of the meeting. Also, the participants enjoyed a delightful evening cruising on the Thames River with dinner and dancing.
OVERVIEW LECTURES
The conference had three special lectures focusing on areas that could have an impact on designing novel therapeutics for cancer gene therapy: the Cell Cycle, Apoptosis, and the Signal Transduction Pathway.
Dr. C. Sherr ( Memphis, TN, USA ) gave an elegant talk on ''G1 Phase Progression and Cancer.'' His talked clearly outlined the complex cell cycle pathways and where key mutations play a role in the pathogenesis of cancer. He described how p53 or Rb modifications /mutations played a pivotal role in the etiology of many cancers. In addition, he helped define the relationship among the cyclin kinases, transcription regulators, DNA synthesis, growth arrest, and apoptosis. His talk set the high scientific standards for the rest of the conference.
Dr. W. El -Diery (Philadelphia, PA, USA ) presented a basic science overview of ''Enhancing Cancer Apoptosis by Therapeutic Design''. The talk discussed the role of the death domains in TNF families and their death receptors. New transcription factor targets were identified, and how these could be exploited by novel gene therapy strategies were discussed.
Dr. J. Norris (Charleston, SC, USA ) discussed the ''Mechanism of the Bystander Effect in Gene Therapy'' using the fas ligand and its receptor as a model system for studying the role of ceramide synthase and low -dose chemotherapy in enhancing tumor cell death. This involved giving a detailed overview of the signal transduction pathways in prostate cancer and possible therapeutic sites for intervention.
ANTITUMOR IMMUNITY
The first day session concentrated on the tumor biology of dendritic cells, T cells, and DNA -based tumor vaccines.
Dr. O. Eremin (Lincoln, England, UK ) gave an outstanding review of the role of dendritic cells in the host defense system in cancer patients. He defined the limitations of these systems and how the immune system fails to recognize or respond to the presentation of cancer cells clinically.
Dr. T. Whiteside ( Pittsburgh, PA, USA ) presented the topic ''DNA -Based Tumor Vaccines.'' The focus of the talk was on antigen presentation to dendritic cells, allogenic stimulation, and IL-2 secretion. A phase 1 clinical study has been designed for oral carcinoma using autologous tumor DNA -based vaccines following surgery.
Dr. P. Walden ( Berlin, Germany ) discussed T-cell responses in melanoma. Using hybrid cell lines of tumor cells and antigen -presenting cells, the data suggested that antitumor immune responses were achievable in melanoma and cutaneous lymphoma patients. This could be a new approach toward tumor vaccinations.
Dr. P. Srivastava (Farmington, CT, USA ) presented on the role of heat shock proteins as modulators of the immune response in cancer. Preclinical data were correlated with patients suggesting that heat shock proteins stimulated macrophages and dendritic cells to secrete inflammatory cytokines and costimulatory molecules.
GENE THERAPY -INDUCED TUMOR APOPTOSIS
There were several talks on how different therapeutic genes could selectively induce apoptosis for the treatment of cancer.
Antiangiogenesis
Antiangiogenesis research was one of the new areas that had developments using hypoxia promoters for vascular-targeting strategies.
Dr. N. Ingram (Institute of Cancer Research, London, England, UK ) presented interesting data on murine leukemia virus that strongly induced gene expression using the hypoxia (HRE ) promoter in 0.5% oxygen. This vector system was shown to have selective expression in hypoxic endothelial cells. These data were very encouraging.
Prodrug strategies
Dr. D. Klatzman (Paris, France ) presented an elegant study comparing graft -versus -host and graft -versus -leukemia effects after ganciclovir -HSV / TK suicide gene therapy of graft -versus -host disease. The TK /ganciclovir system permitted the maintenance and control of alloreactivity until a graft -versus -leukemia effect was obtained. This model may be a potential therapeutic approach for allogenic hematopoietic stem cell transplantation. This was one of the most exciting talks presented at the conference.
RNA metabolism and antisense strategies
Dr. M. Garcia -Blanco (Intronn, NC, USA ) talked on spliceosome -mediated RNA trans -splicing, which can mobilize exonic packets of genetic information to reprogram messenger RNA. Application of this technology was demonstrated in the restoration of CFTR gene (exon -10 ) function in lung cells.
Dr. G. Dickson (Royal Holloway College, London, England, UK ) presented work on gene repair strategies using 2 -O -methyl -RNA /DNA hybrid structures called ''Chimeraplasty.'' Examples of these studies were shown for cardiovascular disease and hepatocellular carcinoma. The strategies offer new methods to develop novel therapeutics.
VECTOR DEVELOPMENT
Dr. D. Darling ( Kings College, London, England, UK ) demonstrated the role of fibronectin in the medium for recovering higher concentrations of retroviruses by centrifugation. High titer (paramagnetic ) retroviral vector preparations were used for magnetic field -dependent retroviral infection in vitro.
Dr. W. Uckert (Berlin, Germany ) demonstrated that a retroviral vector pseudotype of an amphotropic murine leukemia virus could transform human T cells using the Pit -1 and -2 receptors of these cells ( CD4 + and CD8 + ).
Promoters
This topic was extensively explored at the conference with both oral presentations and poster sessions. Interesting new applications for unique promoter systems were unveiled. Dr. V. Jerome (Marburg, Germany ) discussed elegant studies with tissue -specific promoters and a Fos/ Jun mutant promoter, demonstrating the utility and sophistication of this technology. These systems will lead to better tumor-specific targeting.
Dr. K. Lipinski ( Cobra Ther., Keele, England, UK ) demonstrated that deregulation of -catenin was associated with selective Wnt (Wingless / Int -1 ) signaling in colon carcinoma cells. These tumor cells, in vivo, were responsive to adenovirus vectors containing a modified catenin promoter and the nitroreductase gene for treatment with the prodrug (CB1954) strategy in primary and secondary sites in the liver.
Dr. J. Dong ( Charleston, SC, USA ) used a tetracycline transactivator gene under the control of a synthetic prostatespecific ( ARR2PB ) promoter to express the Fas ligand gene in mouse model systems with minimum host toxicity. Tumor selectivity using the Fas ligand in LNCaP prostate carcinoma Dr. M. Quigg ( University of Glasgow, Scotland ) demonstrated that malignant cells could be sensitized to radiation by transduction of a noradrenaline transporter gene and radiolabeled meta -iodobenzylguanidine in glioma cells. Additional studies are enhancing the specificity of the promoter with the human telomerase promoter.
Viral vectors
Retrovirus. Dr. M. Collins' ( University College, London, England, UK ) group presented research on the ability of HIV-1 vectors to transduce human monocytes, macrophages, and dendritic cells. The focus of these studies was to develop an efficient protocol for antigen gene delivery to human antigen -presenting cells.
Dr. J. Gaken ( Kings College, London, England, UK ) has used Fusagene vectors to deliver multiple genes from a single cistron. These retroviruses, which were constructed to deliver cytokines and B7.1 antigens, demonstrated biological activity in murine systems. Adenovirus. Dr. R. Crystal (New York, NY, USA ) discussed studies on the development of adenoviruses for transducing dendritic cells with interleukin -12. He concluded that CD40 ligand was the most efficacious for transducing dendritic cells. Dr. A. Deisseroth (New Haven, CT, USA ) used the Lplastin promoter in a replication -incompetent adenoviral vector and showed expression in ovarian carcinoma but not in non-neoplastic tissue. The cytosine deaminase gene was then cloned into the vector and the tumor cells were treated with 5 -fluorocytosine, resulting in selective cytotoxicity to the tumor. These studies showed improved adenoviral vector selectivity for different types of human tumors.
Dr. Y. Guo ( Shanghai, China ) demonstrated the utility of treating hepatocellular carcinoma using a combination modality treatment including an adenoviral vector expressing Flt -3 ligand. The Flt -3 ligand was able to generate cellular immune responses. When combined with 5-FU, this strategy was shown to be more effective than either modality alone.
Nonviral vectors
Dr. A. Miller ( London, England, UK ) gave a synopsis of the current nonviral delivery field. He discussed the problems of chemical synthesis of cationic liposomes and their pharmacological distribution in the tumor cell. He helped define criteria for the next generation of nonviral lipids and the challenges that lie ahead.
Dr. E. Chang ( Washington, DC, USA ) presented data using p53 gene therapy in a synergistic combination with radiation and chemotherapy. The p53 vector was delivered with folate ligands in lipid membranes for tumor specificity in mouse model systems.
REPLICATION -COMPETENT VIRUSES
Dr. R. Coffin ( Bio Vex, England, UK ) gave an insightful talk on the herpes simplex virus (HSV ) and its capacity to replicate in tumor cells. Original clinical HSV isolates resulted in enhanced tumor selectivity and stronger lytic potential than HSV laboratory strains previously studied. These observations were very useful for the development of effective replication -competent viral vectors. This talk was one of the highlights of the meeting.
CLINICAL DATA
Dr. D. Kirn ( London, England, UK ) gave an excellent summary on the preclinical /clinical data for the replication-competent adenovirus (ONXY-015 ). He reviewed the status of these viruses and their modifications and then clearly summarized the clinical studies for dosing, common toxicities including fever /pain, and clinically relevant hepatotoxicity. He explained future studies of the role of the E1A and E3 regions of the virus. It is hoped that these modifications would enhance the potency of replication. Other modifications on the coat proteins, or investigation of the bystander effect, or additional therapeutic genes would add to the efficacy and selectivity of tumor toxicity. Dr. N. Habib ( Imperial College, London, England, UK ) presented phase I data on the use of adenovirus vectors with deleted E1B region for the treatment of patients with hepatocellular carcinoma. Toxicity studies demonstrated tolerance of the viral vector with grades I-II fever and no significant rise in liver enzymes. Of the five patients, one had a partial response and four showed disease progression. The conclusion was that more effective vectors were required for a clinical impact.
